Handelen Exicure, Inc. - XCUR CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.09 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.030779% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | -0.013666% | ||||||||
Tijd van overnight-tarief | 22:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Prev. Close* | 1.41 |
Open* | 1.38 |
1-Jaarlijkse Verandering* | 626.32% |
Dagelijks bereik* | 1.38 - 1.52 |
52 wekelijks bereik | 0.63-10.16 |
Weekgemiddelde volume (10 dagen) | 21.02K |
Gemiddeld volume (3 maanden) | 4.96M |
Marktkapitalisatie | 6.85M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 4.96M |
Omzet | 9.17M |
EPS | -9.35 |
Dividend (opbrengst %) | N/A |
Beta | 0.98 |
Volgende inkomsten datum | Mar 23, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Feb 2, 2023 | 1.41 | 0.04 | 2.92% | 1.37 | 1.46 | 1.36 |
Feb 1, 2023 | 1.36 | -0.03 | -2.16% | 1.39 | 1.39 | 1.35 |
Jan 31, 2023 | 1.38 | 0.05 | 3.76% | 1.33 | 1.40 | 1.31 |
Jan 30, 2023 | 1.35 | -0.04 | -2.88% | 1.39 | 1.39 | 1.30 |
Jan 27, 2023 | 1.38 | 0.01 | 0.73% | 1.37 | 1.39 | 1.34 |
Jan 26, 2023 | 1.36 | 0.01 | 0.74% | 1.35 | 1.41 | 1.27 |
Jan 25, 2023 | 1.36 | -0.01 | -0.73% | 1.37 | 1.46 | 1.35 |
Jan 24, 2023 | 1.40 | 0.03 | 2.19% | 1.37 | 1.42 | 1.36 |
Jan 23, 2023 | 1.41 | -0.07 | -4.73% | 1.48 | 1.48 | 1.37 |
Jan 20, 2023 | 1.43 | 0.09 | 6.72% | 1.34 | 1.46 | 1.31 |
Jan 19, 2023 | 1.34 | 0.00 | 0.00% | 1.34 | 1.38 | 1.30 |
Jan 18, 2023 | 1.37 | 0.07 | 5.38% | 1.30 | 1.47 | 1.26 |
Jan 17, 2023 | 1.30 | 0.03 | 2.36% | 1.27 | 1.31 | 1.24 |
Jan 13, 2023 | 1.22 | 0.04 | 3.39% | 1.18 | 1.30 | 1.18 |
Jan 12, 2023 | 1.19 | -0.14 | -10.53% | 1.33 | 1.37 | 1.18 |
Jan 11, 2023 | 1.40 | 0.06 | 4.48% | 1.34 | 1.43 | 1.34 |
Jan 10, 2023 | 1.36 | 0.09 | 7.09% | 1.27 | 1.40 | 1.27 |
Jan 9, 2023 | 1.32 | -0.11 | -7.69% | 1.43 | 1.44 | 1.26 |
Jan 6, 2023 | 1.48 | 0.05 | 3.50% | 1.43 | 1.51 | 1.43 |
Jan 5, 2023 | 1.46 | 0.01 | 0.69% | 1.45 | 1.54 | 1.35 |
Exicure, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale inkomsten | 1.036 | 9.719 | 0.118 | 1.296 | 16.613 | -0.483 |
Inkomsten | 1.036 | 9.719 | 0.118 | 1.296 | 16.613 | -0.483 |
Totale bedrijfskosten | 17.198 | 21.154 | 21.937 | 27.913 | 42.049 | 62.066 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 3.539 | 7.046 | 7.818 | 8.573 | 9.955 | 13.087 |
Onderzoek & Ontwikkeling | 13.659 | 14.108 | 14.119 | 19.34 | 32.094 | 48.979 |
Bedrijfsresultaat | -16.162 | -11.435 | -21.819 | -26.617 | -25.436 | -62.549 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.724 | -0.795 | -0.672 | -0.065 | 0.446 | -1.542 |
Overige, Netto | -0.055 | 0.191 | 0.078 | 0.379 | 0.322 | -0.011 |
Netto inkomen voor belastingen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Netto inkomen na belastingen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Netto inkomen voor extra. Posten | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Netto inkomen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Verwaterd Netto Inkomen | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Verwaterd Gewogen Gemiddelde Aandelen | 1.3099 | 1.3099 | 1.37284 | 1.9222 | 2.9065 | 2.95362 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -12.9331 | -9.1908 | -16.3261 | -13.6838 | -8.4872 | -21.7029 |
Verwaterde Genormaliseerde Winst per Aandeel | -12.9331 | -9.1908 | -16.3261 | -13.6838 | -8.4872 | -21.7029 |
Totale buitengewone posten | 0 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 0.997 | 0.079 | -3.677 | 2.118 | 2.565 |
Inkomsten | 0.997 | 0.079 | -3.677 | 2.118 | 2.565 |
Totale bedrijfskosten | 13.154 | 13.941 | 19.404 | 15.567 | 10.302 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 2.892 | 3.098 | 2.947 | 4.15 | 3.162 |
Onderzoek & Ontwikkeling | 10.262 | 10.843 | 16.457 | 11.417 | 7.14 |
Bedrijfsresultaat | -12.157 | -13.862 | -23.081 | -13.449 | -7.737 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | -0.32 | -0.405 | -0.445 | -0.372 | -0.591 |
Overige, Netto | 0 | -0.002 | -0.005 | -0.004 | -0.02 |
Netto inkomen voor belastingen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Netto inkomen na belastingen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Netto inkomen voor extra. Posten | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Netto inkomen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Verwaterd Netto Inkomen | -12.477 | -14.269 | -23.531 | -13.825 | -8.348 |
Verwaterd Gewogen Gemiddelde Aandelen | 2.92812 | 2.93449 | 2.93654 | 3.01522 | 4.03093 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -4.2611 | -4.86252 | -8.01317 | -4.58507 | -2.07099 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Verwaterde Genormaliseerde Winst per Aandeel | -4.2611 | -4.86252 | -8.01317 | -4.58507 | -2.07099 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totaal vlottende activa | 20.041 | 27.638 | 27.663 | 112.776 | 86.322 | 43.666 |
Geldmiddelen en kortetermijnbeleggingen | 19.623 | 25.764 | 26.268 | 110.786 | 82.08 | 39.141 |
Geldmiddelen & Equivalenten | 19.623 | 25.764 | 26.268 | 48.46 | 33.262 | 34.644 |
Totale Vorderingen, Netto | 0.015 | 0.03 | 0.013 | 0.271 | 0.011 | 0 |
Accounts Receivable - Trade, Net | 0 | 0.013 | 0.003 | 0.035 | 0.011 | 0 |
Prepaid Expenses | 0.403 | 1.844 | 1.382 | 1.014 | 4.231 | 3.247 |
Total Assets | 20.576 | 28.987 | 28.756 | 115.263 | 100.444 | 64.868 |
Property/Plant/Equipment, Total - Net | 0.503 | 1.317 | 1.061 | 2.455 | 12.729 | 11.877 |
Property/Plant/Equipment, Total - Gross | 1.12 | 2.166 | 2.25 | 3.772 | 14.469 | 14.544 |
Accumulated Depreciation, Total | -0.617 | -0.849 | -1.189 | -1.317 | -1.74 | -2.667 |
Other Long Term Assets, Total | 0.032 | 0.032 | 0.032 | 0.032 | 1.393 | 9.325 |
Total Current Liabilities | 12.158 | 3.356 | 2.043 | 31.087 | 13.734 | 34.067 |
Accounts Payable | 0.509 | 1.049 | 0.5 | 1.814 | 1.866 | 3.413 |
Accrued Expenses | 2.16 | 1.273 | 1.543 | 2.435 | 3.525 | 6.464 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.213 | 0 | 4.965 | 0 | 6.873 | |
Other Current Liabilities, Total | 8.276 | 1.034 | 0 | 21.873 | 8.343 | 17.317 |
Total Liabilities | 18.128 | 9.012 | 7.804 | 34.516 | 38.938 | 53.636 |
Total Long Term Debt | 4.655 | 4.855 | 4.925 | 0 | 16.589 | 0 |
Long Term Debt | 4.655 | 4.855 | 4.925 | 0 | 16.589 | 0 |
Other Liabilities, Total | 1.315 | 0.801 | 0.836 | 3.429 | 8.615 | 19.569 |
Total Equity | 2.448 | 19.975 | 20.952 | 80.747 | 61.506 | 11.232 |
Preferred Stock - Non Redeemable, Net | 42.63 | 0 | 0 | |||
Common Stock | 0 | 0.004 | 0.004 | 0.009 | 0.009 | 0.011 |
Additional Paid-In Capital | -17.578 | 53.586 | 75.942 | 162.062 | 167.379 | 181.29 |
Retained Earnings (Accumulated Deficit) | -22.604 | -33.615 | -54.994 | -81.297 | -105.965 | -170.067 |
Total Liabilities & Shareholders’ Equity | 20.576 | 28.987 | 28.756 | 115.263 | 100.444 | 64.868 |
Total Common Shares Outstanding | 1.18368 | 1.3099 | 1.47845 | 2.86869 | 2.92142 | 3.62574 |
Korte Termijn Investeringen | 62.326 | 48.818 | 4.497 | |||
Other Current Assets, Total | 0.705 | 1.278 | ||||
Other Equity, Total | -0.027 | 0.083 | -0.002 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 73.987 | 60.647 | 64.147 | 43.666 | 29.182 |
Geldmiddelen en kortetermijnbeleggingen | 67.436 | 56.059 | 60.838 | 39.141 | 26.384 |
Geldmiddelen & Equivalenten | 34.296 | 42.587 | 51.885 | 34.644 | 23.89 |
Korte Termijn Investeringen | 33.14 | 13.472 | 8.953 | 4.497 | 2.494 |
Totale Vorderingen, Netto | 0.224 | 0.044 | 0.027 | 0 | |
Accounts Receivable - Trade, Net | 0 | 0 | 0 | 0 | |
Prepaid Expenses | 5.02 | 3.642 | 2.173 | 3.247 | 1.669 |
Other Current Assets, Total | 1.307 | 0.902 | 1.109 | 1.278 | 1.129 |
Total Assets | 87.948 | 74.467 | 77.9 | 64.868 | 41.896 |
Property/Plant/Equipment, Total - Net | 12.535 | 12.383 | 12.288 | 11.877 | 11.393 |
Property/Plant/Equipment, Total - Gross | 14.346 | 14.473 | 14.661 | 14.544 | 14.359 |
Accumulated Depreciation, Total | -1.811 | -2.09 | -2.373 | -2.667 | -2.966 |
Other Long Term Assets, Total | 1.426 | 1.437 | 1.465 | 9.325 | 1.321 |
Total Current Liabilities | 12.763 | 12.745 | 21.98 | 34.067 | 21.361 |
Accounts Payable | 2.976 | 2.25 | 2.485 | 3.413 | 1.918 |
Accrued Expenses | 2.441 | 3.228 | 5.48 | 6.464 | 3.227 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 7.346 | 7.267 | 14.015 | 17.317 | 16.216 |
Total Liabilities | 37.907 | 37.827 | 63.917 | 53.636 | 38.66 |
Total Long Term Debt | 16.659 | 16.73 | 16.801 | 0 | 0 |
Long Term Debt | 16.659 | 16.73 | 16.801 | 0 | |
Other Liabilities, Total | 8.485 | 8.352 | 25.136 | 19.569 | 17.299 |
Total Equity | 50.041 | 36.64 | 13.983 | 11.232 | 3.236 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.009 | 0.009 | 0.009 | 0.011 | 0.012 |
Additional Paid-In Capital | 168.442 | 169.337 | 170.217 | 181.29 | 181.644 |
Retained Earnings (Accumulated Deficit) | -118.442 | -132.711 | -156.242 | -170.067 | -178.415 |
Other Equity, Total | 0.032 | 0.005 | -0.001 | -0.002 | -0.005 |
Total Liabilities & Shareholders’ Equity | 87.948 | 74.467 | 77.9 | 64.868 | 41.896 |
Total Common Shares Outstanding | 2.93283 | 2.93626 | 2.93666 | 3.62574 | 4.0931 |
Current Port. of LT Debt/Capital Leases | 6.873 | 0 |
- Jaarlijks
- Per kwartaal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -16.941 | -12.039 | -22.413 | -26.303 | -24.668 | -64.102 |
Geldmiddelen uit Operationele Activiteiten | -5.05 | -19.789 | -19.487 | 1.317 | -39.27 | -34.819 |
Geldmiddelen uit Operationele Activiteiten | 0.18 | 0.232 | 0.358 | 0.392 | 0.766 | 1.123 |
Niet-Geldelijke Posten | 0.942 | 1.437 | 2.179 | 1.981 | 2.896 | 4.048 |
Veranderingen in het Operationeel Kapitaal | 10.769 | -9.419 | 0.389 | 25.247 | -18.264 | 24.112 |
Geldmiddelen uit Investeringsactiviteiten | -0.394 | -0.926 | -0.094 | -63.432 | 10.142 | 43.085 |
Kapitaaluitgaven | -0.394 | -0.926 | -0.094 | -1.082 | -3.171 | -0.968 |
Geldmiddelen uit Financieringsactiviteiten | 6.336 | 26.856 | 20.085 | 84.307 | 15.13 | 1.116 |
Financiering van Cash Flow Posten | -0.147 | -3.699 | -1.957 | -6.518 | -0.711 | -1.125 |
Uitgifte (Aflossing) van aandelen, netto | 0.483 | 31.556 | 22.042 | 90.825 | 3.34 | 12.241 |
Uitgifte (Aflossing) van Schulden, Netto | 6 | -1.001 | 0 | 12.501 | -10 | |
Nettowijziging in Geldmiddelen | 0.892 | 6.141 | 0.504 | 22.192 | -13.998 | 9.382 |
Overige Cash Flow investeringsposten, Totaal | -62.35 | 13.313 | 44.053 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -12.477 | -26.746 | -50.277 | -64.102 | -8.348 |
Cash From Operating Activities | -14.809 | -25.885 | -21.022 | -34.819 | -12.756 |
Cash From Operating Activities | 0.263 | 0.546 | 0.829 | 1.123 | 0.302 |
Non-Cash Items | 0.693 | 1.578 | 3.04 | 4.048 | 1.006 |
Changes in Working Capital | -3.288 | -1.263 | 25.386 | 24.112 | -5.716 |
Cash From Investing Activities | 15.297 | 34.533 | 38.977 | 43.085 | 1.995 |
Capital Expenditures | -0.225 | -0.564 | -0.623 | -0.968 | -0.006 |
Other Investing Cash Flow Items, Total | 15.522 | 35.097 | 39.6 | 44.053 | 2.001 |
Cash From Financing Activities | 0.546 | 0.677 | 0.668 | 1.116 | -7.993 |
Financing Cash Flow Items | 0 | 0 | -0.009 | -1.125 | -0.507 |
Issuance (Retirement) of Stock, Net | 0.546 | 0.677 | 0.677 | 12.241 | 0.014 |
Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | -10 | -7.5 |
Net Change in Cash | 1.034 | 9.325 | 18.623 | 9.382 | -18.754 |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com GroupHandelaren
Actieve klanten per maand
Maandelijks beleggingsvolume
Opgenomen per maand
Handelscalculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Exicure, Inc. Company profile
Over Exicure, Inc.
Exicure, Inc. is een biotechnologiebedrijf in een klinische fase. Het bedrijf houdt zich bezig met de ontwikkeling van therapeutica voor neurologie, immuno-oncologie, ontstekingsziekten en andere genetische aandoeningen op basis van zijn sferisch nucleïnezuur (SNA) technologie. De Vennootschap ontwikkelt XCUR-FXN, een op sferisch nucleïnezuur (SNA) gebaseerde therapeutische kandidaat voor de behandeling van ataxie van Friedreich (FA). XCUR-FXN bevat dankzij zijn SNA-technologie meer dan één actieve oligonucleotide in één enkele SNA-molecule. De therapeutische kandidaat van de Vennootschap cavrotolimod (AST-008) is een toll-like receptor 9 (TLR9) agonist, ontworpen voor immuno-oncologische toepassingen, gebruik makend van haar SNA-technologie. AST-008 is in een Fase I b/II klinische studie bij patiënten met vergevorderde vaste tumoren. TLR9 agonisten binden aan en activeren TLR9.
Industry: | Bio Therapeutic Drugs |
2430 N. Halsted St.
CHICAGO
ILLINOIS 60614
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 485.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen